Lenacapavir

Lenacapavir
Clinical data
Pronunciation	/ˌlɛnəˈkæpəvɪər/; LEN-ə-KAP-ə-veer
Trade names	Sunlenca, others
Other names	GS-CA2, GS-6207
AHFS/Drugs.com	Monograph
MedlinePlus	a623005
License data	US DailyMed: Lenacapavir;
Pregnancy; category	AU: B1;
Routes of; administration	By mouth, subcutaneous
Drug class	Capsid inhibitors
ATC code	J05AX31 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name N-[(1S)-1-{3-[4-chloro-3-(methanesulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl]-6-[3-(methanesulfonyl)-3-methylbut-1-yn-1-yl]pyridin-2-yl}-2-(3,5-difluorophenyl)ethyl]-2-[(3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl]acetamide;
CAS Number	2189684-44-2;
DrugBank	DB15673;
ChemSpider	81367881;
UNII	A9A0O6FB4H;
KEGG	D12161; D12162;
ChEMBL	ChEMBL4594438;
PDB ligand	QNG (PDBe, RCSB PDB);
Chemical and physical data
Formula	C39H32ClF10N7O5S2
Molar mass	968.28 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(C#Cc1ccc(-c2ccc(Cl)c3c(NS(C)(=O)=O)nn(CC(F)(F)F)c23)c([C@H](Cc2cc(F)cc(F)c2)NC(=O)Cn2nc(C(F)(F)F)c3c2C(F)(F)[C@@H]2C[C@H]32)n1)S(C)(=O)=O;
	InChI InChI=1S/C39H32ClF10N7O5S2/c1-36(2,63(3,59)60)10-9-21-5-6-22(23-7-8-26(40)30-32(23)57(17-37(43,44)45)54-35(30)55-64(4,61)62)31(51-21)27(13-18-11-19(41)14-20(42)12-18)52-28(58)16-56-34-29(33(53-56)39(48,49)50)24-15-25(24)38(34,46)47/h5-8,11-12,14,24-25,27H,13,15-17H2,1-4H3,(H,52,58)(H,54,55)/t24-,25+,27-/m0/s1; Key:BRYXUCLEHAUSDY-WEWMWRJBSA-N;

Lenacapavir, sold under the brand name Sunlenca, is an antiretroviral medication used to treat and prevent HIV/AIDS. It is taken by mouth or by subcutaneous injection. Lenacapavir is a human immunodeficiency virus type 1 (HIV-1) capsid inhibitor.

The most common side effects include reactions at the injection site and nausea.

Lenacapavir was approved for medical treatment in the European Union in August 2022, in Canada in November 2022, and in the United States in December 2022. It is the first of a class of drugs called capsid inhibitors to be approved by the US Food and Drug Administration (FDA) for treating HIV/AIDS. In June 2025, it received approval in the US for HIV prevention.

Clinical data

Pronunciation	/ˌlɛnəˈkæpəvɪər/ LEN-ə-KAP-ə-veer
Trade names	Sunlenca, others
Other names	GS-CA2, GS-6207
AHFS/Drugs.com	Monograph
MedlinePlus	a623005
License data	US DailyMed: Lenacapavir
Pregnancy category	AU: B1
Routes of administration	By mouth, subcutaneous
Drug class	Capsid inhibitors
ATC code	J05AX31 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only US: ℞-only EU: Rx-only
Identifiers
IUPAC name N-[(1S)-1-{3-[4-chloro-3-(methanesulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl]-6-[3-(methanesulfonyl)-3-methylbut-1-yn-1-yl]pyridin-2-yl}-2-(3,5-difluorophenyl)ethyl]-2-[(3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl]acetamide
CAS Number	2189684-44-2
DrugBank	DB15673
ChemSpider	81367881
UNII	A9A0O6FB4H
KEGG	D12161 D12162
ChEMBL	ChEMBL4594438
PDB ligand	QNG (PDBe, RCSB PDB)
Chemical and physical data
Formula	C₃₉H₃₂ClF₁₀N₇O₅S₂
Molar mass	968.28 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC(C)(C#Cc1ccc(-c2ccc(Cl)c3c(NS(C)(=O)=O)nn(CC(F)(F)F)c23)c([C@H](Cc2cc(F)cc(F)c2)NC(=O)Cn2nc(C(F)(F)F)c3c2C(F)(F)[C@@H]2C[C@H]32)n1)S(C)(=O)=O
InChI InChI=1S/C39H32ClF10N7O5S2/c1-36(2,63(3,59)60)10-9-21-5-6-22(23-7-8-26(40)30-32(23)57(17-37(43,44)45)54-35(30)55-64(4,61)62)31(51-21)27(13-18-11-19(41)14-20(42)12-18)52-28(58)16-56-34-29(33(53-56)39(48,49)50)24-15-25(24)38(34,46)47/h5-8,11-12,14,24-25,27H,13,15-17H2,1-4H3,(H,52,58)(H,54,55)/t24-,25+,27-/m0/s1 Key:BRYXUCLEHAUSDY-WEWMWRJBSA-N